Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India

Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)

PRO 2000 Gel is designed to be inserted into the vagina to protect women from getting HIV during sex. So far, PRO 2000 Gel has been tested for safety in 136 women from Europe and the United States. This study will evaluate the safety and acceptability of PRO 2000 Gel when used by women in Pune, India. The study will also examine what Indian women and men think about using PRO 2000 Gel.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Topical microbicides are designed to prevent the sexual transmission of HIV and other disease pathogens. PRO 2000/5 Gel (P), or PRO 2000, is a vaginal microbicide that has been evaluated in Phase I safety trials in Europe and the U.S. PRO 2000 Gel is easily manufactured, highly stable, and highly water-soluble. The aqueous gel formulation contains a synthetic carbomer, a lactic acid/lactate buffer, and preservatives. In vitro, PRO 2000 Gel has been shown to suppress infection by herpes viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, and a wide range of HIV-1 isolates. This study will evaluate the safety and acceptability of PRO 2000 Gel in HIV uninfected women in Pune, India. The study is a precursor to a larger Phase II/III study of PRO 2000 Gel.

Participants in this study will be sexually active HIV uninfected women at either low or high risk for HIV infection. Male partners of these women will also be enrolled in the study. Participants will be asked to apply PRO 2000 Gel twice a day for 14 consecutive days between menses and to have vaginal intercourse with a single male partner, using study-provided male condoms, at least twice per week during the two weeks of PRO 2000 Gel use. Participants will have a screening visit, an enrollment visit, and 3 study visits during the two weeks of PRO 2000 Gel use; each visit will last about 1 hour. Study visits will include a medical history, gynecologic exam, blood and urine tests, and product acceptability questionnaires. Colposcopy will be performed three times during the study. Participants will also be asked to complete a Daily Study Record about product use and sexual activity and questionnaires about their willingness to use the product and their perceptions of the product.

Four weeks after using PRO 2000 Gel, participants will be asked to participate in a focus group to discuss product acceptability. Participants' male partners will also be asked to participate in focus groups about product use.

Type d'étude

Interventionnel

Inscription

120

Phase

  • La phase 1

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria for All Female Participants:

  • Age 18 to 45
  • HIV uninfected
  • Regular menstrual cycle of at least 21 days or no menstrual cycle because of long-acting progestin use
  • No change in hormonal contraceptive use in the 3 months prior to study entry
  • Agree to use acceptable methods of contraception during the study
  • Normal Pap smear at screening or in the 3 months prior to study entry
  • Sexually active with a single male sexual partner who is eligible for the study
  • Agree to abstain from sexual intercourse for 48 hours before the enrollment visit
  • Willing to complete Daily Study Records
  • Agree to follow study directions about PRO 2000 Gel use and sexual activity during the study

Additional Inclusion Criteria for Female Participants at Higher Risk for HIV Infection:

  • Sexually transmitted disease (STD) in the 3 months prior to study entry
  • Current male partner has had an STD in the 3 months prior to study entry

Inclusion Criteria for Male Partners of Female Participants:

  • Age 18 years or older
  • HIV uninfected
  • No STD symptoms at study entry
  • Agree to abstain from sexual intercourse for 48 hours before the enrollment visit
  • Agree to have vaginal intercourse only with partner who is taking part in the study
  • Agree to have vaginal intercourse at least twice a week while in the study and to use study provided male condoms

Exclusion Criteria for All Female Participants:

  • Menopausal
  • Breastfeeding
  • Used non-therapeutic intravenous drugs within 1 year of study
  • Currently pregnant or have been pregnant in the 3 months prior to study entry
  • Serious liver, kidney, or blood abnormalities
  • Urinary tract infection as determined by positive urine culture
  • Genital abnormality
  • History of adverse reaction to anticoagulants
  • History of sensitivity or allergy to latex
  • Used any spermicide or spermicidally lubricated condom in the week prior to study entry
  • Participated in any investigational drug trial in 30 days prior to study entry
  • Used an intrauterine contraceptive device in the 3 months prior to study entry
  • Abnormal Pap smear in the 3 months prior to study entry
  • Gynecological surgery in the 3 months prior to study entry
  • Breakthrough menstrual bleeding in the 3 months prior to study entry
  • Vaginal bleeding during or following intercourse in the 3 months prior to study entry

Additional Exclusion Criteria for Female Participants at Low Risk for HIV Infection:

  • STD or pelvic inflammatory disease in the 3 months prior to study entry
  • Current male partner has had an STD in the 3 months prior to study entry
  • Current male partner has injected non-therapeutic drugs in the 3 months prior to study entry
  • Signs on pelvic exam consistent with an STD other than bacterial vaginosis

Exclusion Criteria for Male Partners of Female Participants

  • History of adverse reaction to latex
  • Refuse examination or treatment for an STD or STD symptoms

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Smita N. Joshi, MBBS, National AIDS Research Institute (Pune, India)
  • Chaise d'étude: Steven J. Reynolds, MD, FRCP(C), Johns Hopkins University Department of Medicine

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates d'inscription aux études

Première soumission

16 avril 2004

Première soumission répondant aux critères de contrôle qualité

16 avril 2004

Première publication (Estimation)

19 avril 2004

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

23 décembre 2009

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 décembre 2009

Dernière vérification

1 novembre 2006

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner